Home » Stocks » SEEL

Seelos Therapeutics, Inc. (SEEL)

Stock Price: $3.36 USD 0.02 (0.60%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 342.14M
Revenue (ttm) n/a
Net Income (ttm) -33.39M
Shares Out 69.05M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $3.36
Previous Close $3.34
Change ($) 0.02
Change (%) 0.60%
Day's Open 3.31
Day's Range 3.31 - 3.44
Day's Volume 2,181,080
52-Week Range 0.56 - 6.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Biotech penny stocks are heating up as Covid cases decline; which small-caps are on your watchlist? The post Trading Biotech Penny Stocks?

Other stocks mentioned: JAGX, TLGT
1 week ago - PennyStocks

The company has been included in the first U.S. psychedelics-focused ETF.

1 week ago - The Motley Fool

NEW YORK, June 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

1 week ago - PRNewsWire

Seelos Therapeutics Inc's (NASDAQ: SEEL) Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Me...

2 weeks ago - Benzinga

NEW YORK, May 27, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

2 weeks ago - PRNewsWire

NEW YORK, May 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disor...

2 weeks ago - PRNewsWire

Looking for penny stocks to buy at a steal? Check these 3 out for some watchlist inspiration The post These 4 Penny Stocks Are Down Today, Time to Buy the Dip?

Other stocks mentioned: BBIG, CIDM, TBLT
3 weeks ago - PennyStocks

NEW YORK, May 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

3 weeks ago - PRNewsWire

NEW YORK, May 20, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disor...

3 weeks ago - PRNewsWire

Top penny stocks in 2021? Check these 3 out for some watchlist inspiration The post Best Penny Stocks to Invest in 2021?

Other stocks mentioned: USWS, XXII
3 weeks ago - PennyStocks

NEW YORK, May 19, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disor...

3 weeks ago - PRNewsWire

Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

Good news from a clinical study was overshadowed by a recommendation downgrade from an analyst.

3 weeks ago - The Motley Fool

Seelos Therapeutics Inc (NASDAQ: SEEL) has announced data from Part 1, the open-label cohort, of its Proof-of-Concept study of SLS-002 for acute suicidal ideation and behavior in patients with Major Dep...

3 weeks ago - Benzinga

NEW YORK, May 17, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disor...

3 weeks ago - PRNewsWire

NEW YORK, May 10, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

1 month ago - PRNewsWire

NEW YORK, April 20, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...

1 month ago - PRNewsWire

NEW YORK, April 19, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...

1 month ago - PRNewsWire

NEW YORK, April 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...

1 month ago - PRNewsWire

NEW YORK, April 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) diso...

Other stocks mentioned: ATR
2 months ago - PRNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AFMD, CMRX, EPZM, WVE
2 months ago - 24/7 Wall Street

SEEL stock has received a massive vote of confidence from a BTIG analyst today who placed a $14 price target on this biotech stock. The post SEEL Stock: Why Biotech Play Seelos Therapeutics Is Soaring T...

3 months ago - InvestorPlace

The stock market has some major movers as noon rolls around on Friday and InvestorPlace is looking at what stocks are up today. The post Midday Market Update: What Stocks Are Up Today?

Other stocks mentioned: EBON, NVAX, NVS, T
3 months ago - InvestorPlace

An analyst is really bullish about the biotech stock.

3 months ago - The Motley Fool

Seelos Therapeutics Inc (NASDAQ: SEEL) has amended the agreement with Vyera Pharmaceuticals AG, announced in March 2018, to develop SLS-002 to repurchase a significant portion of the royalties payable o...

3 months ago - Benzinga

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

3 months ago - PRNewsWire

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

4 months ago - PRNewsWire

NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

4 months ago - PRNewsWire

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based cl...

Other stocks mentioned: NVS, ALLO, SELB
4 months ago - Benzinga

NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

4 months ago - PRNewsWire

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: FLDM, ADMP, BCRX
4 months ago - Benzinga

NEW YORK, Jan. 22, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

4 months ago - PRNewsWire

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

4 months ago - PRNewsWire

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

5 months ago - PRNewsWire

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

5 months ago - PRNewsWire

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

5 months ago - PRNewsWire

NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

7 months ago - PRNewsWire

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

9 months ago - PRNewsWire

NEW YORK, Sept. 4, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

9 months ago - PRNewsWire

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

9 months ago - PRNewsWire

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

9 months ago - PRNewsWire

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

10 months ago - PRNewsWire

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

10 months ago - PRNewsWire

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

10 months ago - PRNewsWire

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shor...

Other stocks mentioned: AGLE, DVAX, LQDA, PHAS
11 months ago - Forbes

SLS-002 Was Safe and Well Tolerated Across All Doses with Resolution of Expected Group Mean Dissociative Side-Effects That Occurred in the Higher Dose Groups Within One Hour Food and Drug Administrati...

11 months ago - GlobeNewsWire

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders an...

11 months ago - GlobeNewsWire

Seelos Therapeutics (NASDAQ: SEEL) shares are trading higher on Thursday after the company announced the initiation of a preclinical study of SLS-004 In Parkinson's Disease.

1 year ago - Benzinga

Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein

1 year ago - GlobeNewsWire

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disor...

1 year ago - GlobeNewsWire

About SEEL

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine... [Read more...]

Industry
Biotechnology
Founded
2016
CEO
Raj Mehra
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
SEEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SEEL stock is "Buy." The 12-month stock price forecast is 9.75, which is an increase of 190.18% from the latest price.

Price Target
$9.75
(190.18% upside)
Analyst Consensus: Buy